Institutional Best Practices for Treating Schizophrenia

Joe Avelino, RN, BSN, MHSA, CPHQ, and Henry Nasrallah, MD, review schizophrenia and the needs of these patients.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the challenges and unmet needs psychiatrists and their teams face when treating patients with schizophrenia and their multiple comorbidities.

Henry Nasrallah, MD, examines schizophrenia relapse, specifically how to diagnose and prevent it before further damage has transpired in the patient’s brain.  

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, explain how to increase patient adherence to treatment and address the stigma associated with schizophrenia even in the family of the patient.

A panel of experts in psychiatric treatment review the burden schizophrenia has on the health care system.

Henry Nasrallah, MD, recalls the history behind long-acting injectables in patients with schizophrenia.

Henry Nasrallah, MD, discusses patient factors that lead to long-acting injectable treatment in patients with schizophrenia.  

Joe Avelino, RN, BSN, MHSA, CPHQ, reviews the benefits of using long-acting injectables (LAIs) and Henry Nasrallah, MD, reviews his techniques for getting patients to accept LAIs and continue with them. 

Henry Nasrallah, MD, and Rahn Bailey, MD, DFAPA, discuss how to switch a patient from oral to a long-acting injectable antipsychotic from their own experience.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, review how early long-acting injectables should be started in patients with schizophrenia.

Joe Avelino, RN, BSN, MHSA, CPHQ, defines a hospital versus an institution; and Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the lack of guideline-supported protocols for patients

Henry Nasrallah, MD, compares the European Guidelines and United States Guidelines; the panel discusses guidelines currently in place for psychiatric patients.

Experts in the field of psychiatry discuss the differences between other specialties and psychiatry as well as the inconsistency within psychiatry itself.

Joe Avelino, RN, BSN, MHSA, CPHQ, describes the patient care protocols upon discharge from the inpatient setting to the outpatient setting to assure that patients will continue their care.

Rahn Bailey, MD, DFAPA, explains why long-acting injectables are under prescribed in patients with schizophrenia and why doctors choose not to use them as a first-line treatment.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Rahn Bailey, MD, DFAPA, explain protocols a practice can follow when managing a patient with schizophrenia who is frequently hospitalized or has other medical conditions.

A panel of experts in schizophrenic psychiatric care share their thoughts on the practice, patients, and treatment based on their years of experience.